A case of episodic angioedema with eosinophilia controlled by anti-IL5 receptor antibody treatment

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the efficacy of anti-IL-5 receptor antibody in controlling episodic angioedema with eosinophilia.
Administered deflazacort and cyclosporine prior to anti-IL-5 receptor antibody treatment.
Treated with anti-IL-5 receptor antibody (benralizumab, 30 mg) administered every 4 weeks.
Monitored variations in blood eosinophils and immunoglobulin levels related to corticosteroid use.
No further attacks of episodic angioedema were observed after starting benralizumab treatment.
Significant reductions in blood eosinophils and symptoms after stopping oral corticosteroids.
Laboratory findings indicated reductions in IgG2, IgG3, and IgG levels due to long-term corticosteroid therapy.

We only have this paper's title and publication details.

Case report shows anti-IL5 receptor antibody effectively controls episodic angioedema with eosinophilia, suggesting a new treatment option.

No takes yet. Share an insight, caveat, or question.

Rhyou et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share